New radioactive tracer could spot hidden cancers

NCT ID NCT05940298

Completed Diagnosis Sponsor: Tomsk National Research Medical Center of the Russian Academy of Sciences Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed phase 1 trial tested a radioactive imaging agent called [99mTc]Tc-DB8 in 10 people with prostate or breast cancer. The goal was to see how the agent spreads in the body and whether it can help detect tumors using SPECT scans. Researchers also checked for safety and compared the images to standard scans like CT or MRI.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: [99mTc]Tc-DB8 (a radioactive imaging agent)
What this could lead to: If successful, this could lead to a new way to detect prostate and breast cancer tumors using SPECT imaging, potentially improving diagnosis.
What could go wrong: This is a very early, small study (10 people) that only looks at imaging, not treatment. The agent may not clearly show tumors or could have safety issues.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER PROSTATE CANCER

Contacts and locations

Locations

TomskNRMC

Tomsk, Russia

More trials for these conditions

Other studies related to the condition(s) this trial covers.